MCID: PLM129
MIFTS: 74

Pulmonary Disease, Chronic Obstructive

Categories: Respiratory diseases

Aliases & Classifications for Pulmonary Disease, Chronic Obstructive

MalaCards integrated aliases for Pulmonary Disease, Chronic Obstructive:

Name: Pulmonary Disease, Chronic Obstructive 53 72 71 41 37
Chronic Obstructive Pulmonary Disease 37 72 36 28 3 59
Copd 53 71 40 3 59
Pulmonary Disease, Chronic Obstructive, Severe Early-Onset 53 13
Pulmonary Disease, Chronic Obstructive, Susceptibility to 28
Severe Early-Onset Chronic Obstructive Pulmonary Disease 71
Chronic Obstructive Pulmonary Disease of Horses 69
Pulmonary Disease Chronic Obstructive 51
Chronic Obstructive Airway Disease 69
Chronic Obstructive Lung Disease 71

Classifications:



External Ids:

OMIM 53 606963
MeSH 41 D029424
KEGG 36 H01714
ICD10 32 J44.0 J44.8
SNOMED-CT via HPO 65 13645005

Summaries for Pulmonary Disease, Chronic Obstructive

MedlinePlus : 40 COPD (chronic obstructive pulmonary disease) makes it hard for you to breathe. The two main types are chronic bronchitis and emphysema. The main cause of COPD is long-term exposure to substances that irritate and damage the lungs. This is usually cigarette smoke. Air pollution, chemical fumes, or dust can also cause it. At first, COPD may cause no symptoms or only mild symptoms. As the disease gets worse, symptoms usually become more severe. They include A cough that produces a lot of mucus Shortness of breath, especially with physical activity Wheezing Chest tightness Doctors use lung function tests, imaging tests, and blood tests to diagnose COPD. There is no cure. Treatments may relieve symptoms. They include medicines, oxygen therapy, surgery, or a lung transplant. Quitting smoking is the most important step you can take to treat COPD. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Pulmonary Disease, Chronic Obstructive, also known as chronic obstructive pulmonary disease, is related to alpha-1-antitrypsin deficiency and respiratory failure, and has symptoms including chronic obstructive pulmonary disease, equilibration disorder and tremor. An important gene associated with Pulmonary Disease, Chronic Obstructive is SERPINA1 (Serpin Family A Member 1), and among its related pathways/superpathways are Pathways in cancer and Selenium Micronutrient Network. The drugs Advair and Anoro Ellipta have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotypes are homeostasis/metabolism and cardiovascular system

OMIM : 53 Chronic obstructive pulmonary disease (COPD) is a common, complex disorder associated with substantial morbidity and mortality. COPD is defined by irreversible airflow obstruction due to chronic bronchitis, emphysema, and/or small airways disease. Airflow obstruction is typically determined by reductions in quantitative spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC) (Silverman et al., 2002; Celedon et al., 2004). (606963)

UniProtKB/Swiss-Prot : 71 Pulmonary disease, chronic obstructive: A common, complex disorder defined by irreversible airflow obstruction due to chronic bronchitis, emphysema, and/or small airways disease. Airflow obstruction is typically determined by reductions in quantitative spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC).

PubMed Health : 59
About copd: COPD, or chronic obstructive pulmonary (PULL-mun-ary) disease, is a progressive disease that makes it hard to breathe. "Progressive" means the disease gets worse over time.COPD can cause coughing that produces large amounts of mucus (a slimy substance), wheezing, shortness of breath, chest tightness, and other symptoms.Cigarette smoking is the leading cause of COPD. Most people who have COPD smoke or used to smoke. Long-term exposure to other lung irritants—such as air pollution, chemical fumes, or dust—also may contribute to COPD.

Wikipedia : 72 Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by... more...

Related Diseases for Pulmonary Disease, Chronic Obstructive

Diseases related to Pulmonary Disease, Chronic Obstructive via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 249)
# Related Disease Score Top Affiliating Genes
1 alpha-1-antitrypsin deficiency 32.1 CXCL8 ELANE ELN SERPINA1
2 respiratory failure 32.1 CRP CXCL8 ELANE PDE4A TNF
3 lung disease 31.7 CXCL8 ELANE ELN PDE4A SERPINA1 TNF
4 bronchiectasis 30.8 CXCL8 ELANE SERPINA1
5 bronchitis 30.5 CXCL8 ELANE RNASE3 SERPINA1 TNF
6 pulmonary emphysema 30.1 ELANE ELN HMOX1 MMP1 MMP12 SERPINA1
7 cystic fibrosis 30.0 ADRB2 CXCL8 ELANE RNASE3 SERPINA1
8 ischemic heart disease 29.9 CRP IL6 TNF
9 pneumonia 29.7 CRP CXCL8 ELANE IL6 TNF
10 interstitial cystitis 29.7 ADRB2 CXCL8 IL6
11 prostatitis 29.6 CXCL8 IL6 TNF
12 bronchiolitis obliterans 29.6 CXCL8 IL6 TNF
13 pneumoconiosis 29.5 CXCL8 IL6 TNF
14 bronchiolitis 29.5 CXCL8 IL6 RNASE3 TNF
15 pulmonary fibrosis, idiopathic 29.5 CXCL8 CXCR2 ELANE MMP1 TNF
16 arteries, anomalies of 29.4 CRP IL6 TNF
17 cystitis 29.4 CRP CXCL8 IL6 TNF
18 chlamydia 29.4 CRP CXCL8 IL6 TNF
19 sleep apnea 29.4 CRP CXCL8 IL6 TNF
20 asthma 29.4 ADAM33 ADRB2 CXCL8 ELANE IL6 MMP1
21 apnea, obstructive sleep 29.4 CRP IL6 TNF
22 periodontitis 29.1 CRP CXCL8 ELANE IL6 MMP1 TNF
23 interstitial lung disease 29.1 CXCL8 IL6 TNF
24 heart disease 29.0 ADRB2 CRP ELN IL6 TNF
25 periodontal disease 29.0 CRP CXCL8 ELANE IL6 MMP1 TNF
26 myocardial infarction 28.6 ADRB2 CRP IL6 MMP1 PTGS1 TNF
27 aspergillosis 11.2
28 pleural disease 11.2
29 multifocal atrial tachycardia 11.2
30 bloom syndrome 10.9
31 pyoderma 10.4 CXCL8 MMP1 TNF
32 pneumothorax 10.4 ELN HMOX1 SERPINA1
33 chronic actinic dermatitis 10.4 ELN MMP1
34 tungiasis 10.4 CXCL8 TNF
35 mid-dermal elastolysis 10.4 ELANE ELN MMP12
36 bronchopulmonary dysplasia 10.4 CXCL8 ELANE RNASE3
37 chronic conjunctivitis 10.3
38 mycobacterium abscessus 10.3 CXCL8 HMOX1 SERPINA1 TNF
39 cardiac rupture 10.3 CRP CXCL8 ELANE
40 scorpion envenomation 10.3 IL6 TNF
41 recurrent corneal erosion 10.3 CXCL8 IL6
42 kashin-beck disease 10.3 MMP1 TNF
43 nose disease 10.3 CXCL8 RNASE3 TNF
44 upper respiratory tract disease 10.3 CXCL8 RNASE3 TNF
45 erysipelas 10.3 ELANE ELN TNF
46 preterm premature rupture of the membranes 10.3 CXCL8 IL6 MMP1
47 bagassosis 10.3 CXCL8 IL6
48 keratoconjunctivitis 10.3 CXCL8 RNASE3 TNF
49 elephantiasis 10.3 ELANE ELN RNASE3
50 pleurisy 10.3 CRP CXCL8 TNF

Graphical network of the top 20 diseases related to Pulmonary Disease, Chronic Obstructive:



Diseases related to Pulmonary Disease, Chronic Obstructive

Symptoms & Phenotypes for Pulmonary Disease, Chronic Obstructive

Clinical features from OMIM:

606963

Human phenotypes related to Pulmonary Disease, Chronic Obstructive:

31
# Description HPO Frequency HPO Source Accession
1 chronic obstructive pulmonary disease 31 HP:0006510

UMLS symptoms related to Pulmonary Disease, Chronic Obstructive:


equilibration disorder, tremor, snoring, coughing, angina pectoris

MGI Mouse Phenotypes related to Pulmonary Disease, Chronic Obstructive:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 HMOX1 ADRB2 IL6 CHRM3 MMP1 CRP
2 cardiovascular system MP:0005385 10.06 HMOX1 ADRB2 IL6 CHRM3 CRP MMP12
3 immune system MP:0005387 9.93 HMOX1 ADRB2 IL6 MMP1 CRP MMP12
4 neoplasm MP:0002006 9.56 IL6 MMP1 CXCR2 PTGS1 ELANE EPHX1
5 respiratory system MP:0005388 9.23 HMOX1 IL6 CHRM3 MMP12 CXCR2 PTGS1

Drugs & Therapeutics for Pulmonary Disease, Chronic Obstructive

PubMedHealth treatment related to Pulmonary Disease, Chronic Obstructive: 59

COPD has no cure yet. However, lifestyle changes and treatments can help you feel better, stay more active, and slow the progress of the disease.The goals of COPD treatment include:Relieving your symptomsSlowing the progress of the diseaseImproving your exercise tolerance (your ability to stay active)Preventing and treating complicationsImproving your overall healthTo assist with your treatment, your family doctor may advise you to see a pulmonologist. This is a doctor who specializes in treating lung disorders.

FDA approved drugs:

(show all 16)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Advair 17 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE GlaxoSmithKline August 2000
2
Anoro Ellipta 17 UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE GlaxoSmithKline December of 2013
3
Arcapta 17 INDACATEROL MALEATE Novartis July 2011
4
Breo Ellipta 17 FLUTICASONE FUROATE; VILANTEROL TRIFENATATE GlaxoSmithKline May 2013
5
Brovana 17 ARFORMOTEROL TARTRATE Sepracor in October 2006
6
Daliresp 17 ROFLUMILAST Forest Pharmaceuticals February 2011
7
DuoNeb 17 ALBUTEROL SULFATE; IPRATROPIUM BROMIDE Dey Laboratories March 2001
8
Foradil Aerolizer 17 FORMOTEROL FUMARATE Novartis February 2001 (asthma, bronchospasm); September 2001 (COPD)
9
Incruse Ellipta 17 UMECLIDINIUM BROMIDE GlaxoSmithKline May 2014
10
Rayos 17 PREDNISONE Horizon Pharma July of 2012
11
Spiriva HandiHaler 17 TIOTROPIUM BROMIDE Boehringer Ingelheim February 2004
12
Stiolto Respimat 17 OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE Boehringer Ingelheim May 2015
13
Striverdi Respimat 17 OLODATEROL HYDROCHLORIDE Boehringer Ingelheim July 2014
14
Tudorza Pressair 17 ACLIDINIUM BROMIDE Forest Laboratories July 2012
15
Utibron Neohaler 17 GLYCOPYRROLATE ; INDACATEROL MALEATE Novartis October 2015
16
Xopenex 17 LEVALBUTEROL HYDROCHLORIDE Sepracor February 2002

Drugs for Pulmonary Disease, Chronic Obstructive (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 641)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4,Phase 3,Phase 2,Early Phase 1 83905-01-5 53477736 447043 55185
2
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 2826718 468682
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
4
Iloprost Approved, Investigational Phase 4,Phase 2,Phase 1 78919-13-8 6443959
5
Terbutaline Approved Phase 4,Phase 3 23031-25-6 5403
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
7
Metoprolol Approved, Investigational Phase 4,Phase 3 51384-51-1, 37350-58-6 4171
8
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51333-22-3 5281004 63006
9
Nitric Oxide Approved Phase 4,Phase 2,Phase 1,Early Phase 1 10102-43-9 145068
10
Simvastatin Approved Phase 4,Phase 3,Phase 1 79902-63-9 54454
11
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
12
Ipratropium Approved Phase 4,Phase 3,Phase 2,Phase 1 22254-24-6, 60205-81-4 43232
13
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3 564-25-0 54671203
14
Cefuroxime Approved Phase 4,Phase 3 55268-75-2 5479529 5361202
15
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 85721-33-1 2764
16
Clarithromycin Approved Phase 4,Phase 3,Early Phase 1 81103-11-9 84029
17
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 151096-09-2, 354812-41-2 152946
18
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
19
Piperacillin Approved Phase 4 66258-76-2 43672
20
Salmon Calcitonin Approved, Investigational Phase 4,Phase 2,Phase 3 47931-85-1 16129616
21
Tazobactam Approved Phase 4 89786-04-9 123630
22
Theophylline Approved Phase 4,Phase 3,Phase 2 58-55-9 2153
23
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 83-43-2 6741
24
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-24-8 5755
25
Fenoterol Approved, Investigational Phase 4,Phase 3 13392-18-2 3343
26
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
27
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
28 Racepinephrine Approved Phase 4 329-65-7
29
Acetylcysteine Approved, Investigational Phase 4,Phase 1,Phase 2 616-91-1 12035
30
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100986-85-4 149096
31
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1 82419-36-1 4583
32
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 50-28-2 5757
33
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 1 57-63-6 5991
34
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 1 35189-28-7 6540478
35
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
36
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2 57-27-2 5288826
37
Metformin Approved Phase 4 657-24-9 4091 14219
38
Adenosine Approved, Investigational Phase 4,Phase 2 58-61-7 60961
39
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
40
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613 2171
41
Infliximab Approved Phase 4,Phase 3 170277-31-3
42 Olodaterol Approved Phase 4,Phase 3,Phase 2,Phase 1 868049-49-4
43
Fosinopril Approved Phase 4 98048-97-6 55891
44
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
45
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
46
Acetazolamide Approved, Vet_approved Phase 4,Phase 3 59-66-5 1986
47
Oxymetazoline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1491-59-4 4636
48
Phenylephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 59-42-7 6041
49
Ketoconazole Approved, Investigational Phase 4,Phase 1 65277-42-1 3823 47576
50
Selenium Approved, Investigational, Vet_approved Phase 4,Phase 3 7782-49-2

Interventional clinical trials:

(show top 50) (show all 3116)

# Name Status NCT ID Phase Drugs
1 Prophylactic Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD) Unknown status NCT00132860 Phase 4 azithromycin
2 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
3 Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
4 Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease Unknown status NCT02563184 Phase 4
5 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT01595750 Phase 4 Roflumilast 500;Placebo
6 Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients Unknown status NCT01131806 Phase 4 fluticasone/ salmeterol 125/25 mcg/puff;fluticasone/ salmeterol 250/25 mcg/puff
7 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01116063 Phase 4 Inhaled iloprost
8 Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease Unknown status NCT01465906 Phase 4 tulobuterol;Tiotropium Bromide;tiotropium bromide
9 The Role of Opinion Leaders in Enhancing Evidence-based Care After Chronic Obstructive Pulmonary Disease (COPD) Emergency Department (ED) Visits Unknown status NCT01107613 Phase 4
10 Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00288548 Phase 4 Metoprolol
11 Exacerbation Prevention GOLD IV COPD With Non Invasive Mechanical Ventilation Unknown status NCT01481727 Phase 4
12 Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial Unknown status NCT00120978 Phase 4 Advair;Flovent
13 Small Airways Evaluation and Treatment Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
14 Strategy to Improve Adherence of Roflumilast Unknown status NCT02018432 Phase 4 Roflumilast escalation dosage;Roflumilast conventional dosage
15 Pulmonary Gas Exchange Response to Indacaterol in COPD Unknown status NCT02547558 Phase 4 Indacaterol
16 Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA Unknown status NCT02546349 Phase 4 fluticasone/salmeterol, tiotropium
17 Simvastatin in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00680641 Phase 4 Simvastatin;Placebo
18 Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD Unknown status NCT00860938 Phase 4 Budesonide
19 The Effects of Continuous Positive Airway Pressure on Overlap Syndrome Unknown status NCT00914264 Phase 4
20 The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD Unknown status NCT01243788 Phase 4 Salmeterol/Fluticasone Propionate
21 Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
22 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD Unknown status NCT02197871 Phase 4
23 Comparing Fluticasone-Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep Unknown status NCT00731770 Phase 4 fluticasone/salmeterol 250/50;placebo
24 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
25 An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD Unknown status NCT02269800 Phase 4 Benzalkonium chloride solution;Normal saline
26 EUROPT Clinical Trial to Study the Efficacy of One-Way Valve Implantation (New Treatment Algorithm) in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
27 Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
28 Efficacy of Bronchial Thermoplasty in Korean Unknown status NCT02031263 Phase 4
29 LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure Unknown status NCT00668408 Phase 4
30 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
31 Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function Unknown status NCT01466712 Phase 4 Tiotropium + formoterol/beclometasone;tiotropium + placebo
32 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections Unknown status NCT02171338 Phase 4
33 Transfusion Strategies in Weaning Patients Unknown status NCT01256645 Phase 4
34 Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion Unknown status NCT01353105 Phase 4
35 Comparative Study of Non-Invasive Mask Ventilation vs Cuirass Ventilation in Patients With Acute Respiratory Failure. Unknown status NCT00331656 Phase 4
36 AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Unknown status NCT01460108 Phase 4
37 Surfactant Administration During Spontaneous Breathing Unknown status NCT01329432 Phase 4
38 Airway Clearance for Prevention of COPD Exacerbation Unknown status NCT00181207 Phase 4
39 A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00857766 Phase 4 ADVAIR DISKUS™ 250/50mcg
40 Metformin in Chronic Obstructive Pulmonary Disease Completed NCT01247870 Phase 4 Metformin;Placebo
41 Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease Completed NCT00984659 Phase 4 Fluticasone propionate/salmeterol combination product;Salmeterol;Placebo
42 Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01397890 Phase 4 Budesonide/formoterol (Symbicort® Turbuhaler®);Tiotropium (SpirivaTM)
43 Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations Completed NCT00115492 Phase 4 Fluticasone Propionate/Salmeterol Combination Product;Salmeterol
44 ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the Completed NCT00144911 Phase 4 Salmeterol;Fluticasone Propionate/Salmeterol Combination Product
45 Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT02786927 Phase 4 Placebo ELLIPTA device;Placebo capsules for use in HANDIHALER device
46 Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease Completed NCT00316992 Phase 4 Ramelteon and Placebo
47 A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pul Completed NCT02982187 Phase 4
48 Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease Completed NCT01124422 Phase 4 fluticasone propionate/salmeterol inhalation powder DISKUS 250/50;tiotropium bromide inhalation powder HandiHaler
49 Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies. Completed NCT00355342 Phase 4 fluticasone propionate/salmeterol powder;salmeterol powder
50 Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease Completed NCT00975195 Phase 4 tiotropium inhalation;salmeterol xinafoate;fluticasone propionate;placebo matched for fluticasone propionate

Search NIH Clinical Center for Pulmonary Disease, Chronic Obstructive

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Pulmonary Disease, Chronic Obstructive:
Adipocell
Bone marrow-derived mononuclear cells for chronic obstructive pulmonary disease
Prochymal
StempeucelCOPD
Embryonic/Adult Cultured Cells Related to Pulmonary Disease, Chronic Obstructive:
Bone marrow-derived mononuclear cells PMIDs: 21653527 23054962 21311694
Bone marrow-derived mesenchymal stem cells PMIDs: 23172272 21653527
Bone marrow-derived mesenchymal stem cells (Stempeucel PMIDs: 18720444

Cochrane evidence based reviews: pulmonary disease, chronic obstructive

Genetic Tests for Pulmonary Disease, Chronic Obstructive

Genetic tests related to Pulmonary Disease, Chronic Obstructive:

# Genetic test Affiliating Genes
1 Chronic Obstructive Pulmonary Disease 28 HMOX1 MMP1 SERPINA1
2 Pulmonary Disease, Chronic Obstructive, Susceptibility to 28

Anatomical Context for Pulmonary Disease, Chronic Obstructive

MalaCards organs/tissues related to Pulmonary Disease, Chronic Obstructive:

38
Lung, Testes, Heart, Endothelial, Bone, Smooth Muscle, Neutrophil

Publications for Pulmonary Disease, Chronic Obstructive

Articles related to Pulmonary Disease, Chronic Obstructive:

(show top 50) (show all 1340)
# Title Authors Year
1
Comparative analysis of salivary sialic acid levels in patients with chronic obstructive pulmonary disease and chronic periodontitis patients: A biochemical study. ( 29442082 )
2018
2
Ventilator-dependent pulmonary nocardiosis in a patient with chronic obstructive pulmonary disease. ( 29319037 )
2018
3
Features of Chronic Obstructive Pulmonary Disease as Predictors of Lung Cancer. ( 29452098 )
2018
4
Perception and Awareness of chronic obstructive pulmonary disease, Chronic Bronchitis and Pulmonary Emphysema in the Spanish Urban Population. ( 29428681 )
2018
5
What Can We Apply to Manage Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Acute Respiratory Failure? ( 29372630 )
2018
6
COPD in Primary Care: Key Considerations for Optimized Management: Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management. ( 29443332 )
2018
7
Chronic Obstructive Pulmonary Disease Exacerbations Are Influenced by Gastroesophageal Reflux Disease. ( 29428028 )
2018
8
NFATc3 and VIP in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease. ( 28125639 )
2017
9
EPHX1 Y113H polymorphism is associated with increased risk of chronic obstructive pulmonary disease in Kazakhstan population. ( 28464990 )
2017
10
Comparison of the role of HHIP SNPs in susceptibility to chronic obstructive pulmonary disease between Chinese Han and Mongolian populations. ( 28939338 )
2017
11
Association Between Antipsychotic Agents and Risk of Acute Respiratory Failure in Patients With Chronic Obstructive Pulmonary Disease. ( 28055066 )
2017
12
Influenza vaccination and risk of respiratory failure in patients with chronic obstructive pulmonary disease: A nationwide population-based case-cohort study. ( 28927683 )
2017
13
White matter lesions characterise brain involvement in moderate to severe chronic obstructive pulmonary disease, but cerebral atrophy does not. ( 28629404 )
2017
14
The copper dependent-lysyl oxidases contribute to the pathogenesis of pulmonary emphysema in chronic obstructive pulmonary disease patients. ( 28965583 )
2017
15
Telehealth Interventions to Support Self-Management of Long-Term Conditions: A Systematic Metareview of Diabetes, Heart Failure, Asthma, Chronic Obstructive Pulmonary Disease, and Cancer. ( 28526671 )
2017
16
Genetic polymorphism of heme oxygenase 1 promoter in the occurrence and severity of chronic obstructive pulmonary disease: a meta-analysis. ( 27998018 )
2017
17
Reduced microRNA-503 expression augments lung fibroblast VEGF production in chronic obstructive pulmonary disease. ( 28880936 )
2017
18
Non-invasive Positive Airway Pressure in Obesity Hypoventilation Syndrome and Chronic Obstructive Pulmonary Disease: Present and Future Perspectives. ( 28485989 )
2017
19
Plasma myostatin levels are related to the extent of right ventricular dysfunction in exacerbation of chronic obstructive pulmonary disease. ( 27323660 )
2017
20
Shelterin Telomere Protection Protein 1 Reduction Causes Telomere Attrition and Cellular Senescence via Sirtuin 1 Deacetylase in Chronic Obstructive Pulmonary Disease. ( 27559927 )
2017
21
Smoking status and gene susceptibility play important roles in the development of chronic obstructive pulmonary disease and lung function decline: A population-based prospective study. ( 28640141 )
2017
22
Factors associated with plasma IL-33 levels in patients with chronic obstructive pulmonary disease. ( 28176939 )
2017
23
Reduced Frizzled Receptor 4 Expression Prevents WNT/I^-Catenin-driven Alveolar Lung Repair in Chronic Obstructive Pulmonary Disease. ( 28245136 )
2017
24
Asthma-chronic obstructive pulmonary disease overlap syndrome - Literature review and contributions towards a Portuguese consensus. ( 28089081 )
2017
25
GDF-15 plasma levels in chronic obstructive pulmonary disease are associated with subclinical coronary artery disease. ( 28245821 )
2017
26
MicroRNA Profiling Reveals a Role for MicroRNA-218-5p in the Pathogenesis of Chronic Obstructive Pulmonary Disease. ( 27409149 )
2017
27
Decreased levels of irisin, a skeletal muscle cell-derived myokine, are related to emphysema associated with chronic obstructive pulmonary disease. ( 28424548 )
2017
28
Neutrophil-mediated IL-6 receptor trans-signaling and the risk of chronic obstructive pulmonary disease and asthma. ( 28334838 )
2017
29
Promoting Physical Activity Using The Internet: Is It Feasible And Acceptable For Patients With Chronic Obstructive Pulmonary Disease (COPD) And Bronchiectasis? ( 28952865 )
2017
30
Up-regulation of Pim-3 in Chronic Obstructive Pulmonary Disease (COPD) patients and its potential therapeutic role in COPD rat modeling. ( 28214201 )
2017
31
The pharmacotherapy preferred by doctors in treatment of patients diagnosed with asthma or chronic obstructive pulmonary disease or allergic rhinitis and concomitant diseases: an epidemiological analysis. ( 28507495 )
2017
32
Apolipoprotein M gene single nucleotide polymorphisms discovery in patients with chronic obstructive pulmonary disease and determined by the base-quenched probe technique. ( 28927745 )
2017
33
Sex-Based Genetic Association Study Identifies CELSR1 as a Possible Chronic Obstructive Pulmonary Disease Risk Locus among Women. ( 27854507 )
2017
34
Low levels of the AhR in chronic obstructive pulmonary disease (COPD)-derived lung cells increases COX-2 protein by altering mRNA stability. ( 28749959 )
2017
35
Chronic obstructive pulmonary disease associated with increased risk of bipolar disorder. ( 28528563 )
2017
36
Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease. ( 28798087 )
2017
37
Increased CTLA-4+ T cells may contribute to impaired T helper type 1 immune responses in patients with chronic obstructive pulmonary disease. ( 28190271 )
2017
38
Expression of GULP1 in bronchial epithelium is associated with the progression of emphysema in chronic obstructive pulmonary disease. ( 28284325 )
2017
39
Eosinophilic biomarkers for detection of acute exacerbation of chronic obstructive pulmonary disease with or without pulmonary embolism. ( 28912870 )
2017
40
Volume doubling time of lung cancer detected in idiopathic interstitial pneumonia: comparison with that in chronic obstructive pulmonary disease. ( 29038933 )
2017
41
The Evaluation of Interstitial Abnormalities in Group B of the 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Classification of Chronic Obstructive Pulmonary Disease (COPD). ( 28924113 )
2017
42
Peripheral Artery Disease in Patients with Chronic Obstructive Pulmonary Disease. ( 28084818 )
2017
43
Early-onset chronic obstructive pulmonary disease in Wilson-Mikity syndrome with preterm birth. ( 28317304 )
2017
44
Association Between ADRB2 Genetic Polymorphisms and the Risk of Chronic Obstructive Pulmonary Disease: A Case-Control Study in a Chinese Population. ( 28753063 )
2017
45
Beta-2-adrenoreceptor polymorphism at position 16 determines the clinical severity of chronic obstructive pulmonary disease. ( 28093224 )
2017
46
Pneumatosis cystoides intestinalis presenting as pneumoperitoneum in a patient with chronic obstructive pulmonary disease: a case report. ( 28241852 )
2017
47
Blood fibrocytes are recruited during acute exacerbations of chronic obstructive pulmonary disease through a CXCR4-dependent pathway. ( 26602164 )
2016
48
Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease. ( 27713627 )
2016
49
Pharmacological inhibition of protein kinase C (PKC)IP downregulates the expression of cytokines involved in the pathogenesis of chronic obstructive pulmonary disease (COPD). ( 27516147 )
2016
50
Impaired nuclear factor erythroid 2-related factor 2 expression increases apoptosis of airway epithelial cells in patients with chronic obstructive pulmonary disease due to cigarette smoking. ( 26861788 )
2016